SynthesisPloS one2015
Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis.
Synthesis in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 7 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2022Pooled it
- Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis.The Cochrane database of systematic reviews · 2021Pooled it
- Romanian clinical guideline for diagnosis and treatment of COPD.The Journal of international medical research · 2020Guideline
- Head-to-head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2019Pooled it
- Adverse events in people taking macrolide antibiotics versus placebo for any indication.The Cochrane database of systematic reviews · 2019Pooled it
- Effects of long-term macrolide therapy at low doses in stable COPD.International journal of chronic obstructive pulmonary disease · 2019Pooled it
- Long-term macrolide treatment for the prevention of acute exacerbations in COPD: a systematic review and meta-analysis.International journal of chronic obstructive pulmonary diseasePooled it
- Trial
- Review
- Review
- Phenotypes of Exacerbations in Chronic Obstructive Pulmonary Disease.Journal of clinical medicine · 2025Review
- Exploiting haem-iron dependence of nontypeableFrontiers in cellular and infection microbiology · 2025Review
- Gut Microbiota Modulation in the Management of Chronic Obstructive Pulmonary Disease: A Literature Review.Cureus · 2024Review
- Management of Refractory Chronic Obstructive Pulmonary Disease: A Review.Life (Basel, Switzerland) · 2024Review
- Impact of prophylactic and 'rescue pack' antibiotics on the airway microbiome in chronic lung disease.BMJ open respiratory research · 2023Observational
- Article
- Systemic and functional effects of continuous azithromycin treatment in patients with severe chronic obstructive pulmonary disease and frequent exacerbations.Frontiers in medicine · 2023Article
- COPD - do the right thing.BMC family practice · 2021Review
- Clinical Significance of Procalcitonin, C-Reactive Protein, and Interleukin-6 in Helping Guide the Antibiotic Use for Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease.Disease markers · 2021Article
- Chronic obstructive pulmonary disease phenotypes: imprint on pharmacological and non-pharmacological therapy.Annals of translational medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute exacerbations of chronic obstructive pulmonary disease (AECOPDs) can lead to high frequencies and rates of hospitalization and mortality. Macrolides are a class of antibiotics that possess both antimicrobial and anti-inflammatory properties. Since the occurrence of AECOPDs is associated with aggravation of airway inflammation and bacterial infections, prophylactic macrolide treatment may be an effective approach towards the prevention of AECOPDs.
methodsWe systemically searched the PubMed, Embase and Cochrane Library databases to identify randomized controlled trials (RCTs) that evaluated the effect of prophylactic macrolide therapy on the prevention of AECOPDs. The primary outcomes were the total number of patients with one or more exacerbations as well as the rate of exacerbations per patient per year.
resultsNine RCTs comprising 1666 patients met the inclusion criteria. Pooled evidence showed macrolides could reduce the frequency of exacerbations in patients with COPD by both unweighted (RR = 0.70; 95% CI: 0.56-0.87; P < 0.01) and weighted approaches (RR = 0.58, 95% CI: 0.43-0.78, P < 0.01). Subgroup analysis showed only 6-12 months of erythromycin or azithromycin therapy could be effective. Moreover, among studies with 6-12 months of azithromycin therapy, both the daily dosing regimen and the intermittent regimen significantly reduced exacerbation rates. The overall number of hospitalizations and the all-cause rate of death were not significantly different between the treatment and control groups. A tendency for more adverse events was found in the treatment groups (OR = 1.55, 95%CI: 1.003-2.39, P = 0.049).
conclusionsOur results suggest 6-12 months erythromycin or azithromycin therapy could effectively reduce the frequency of exacerbations in patients with COPD. However, Long-term treatment may bring increased adverse events and the emergence of macrolide-resistance. A recommendation for the prophylactic use of macrolide therapy should weigh both the advantages and disadvantages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.